Oct 31 (Reuters) - Eli Lilly and Co :
* VERVE THERAPEUTICS INC: CO AND LILLY RELATIONSHIP EXPANDS TO INCLUDE VERVE'S IN VIVO GENE EDITING PROGRAMS TARGETING PCSK9 AND ANGPTL3
* VERVE THERAPEUTICS INC: FOR PCSK9 AND ANGPTL3 PRODUCT CANDIDATES, LILLY NOW HOLDS PRODUCT RIGHTS PREVIOUSLY HELD BY BEAM
* VERVE THERAPEUTICS INC: VERVE HOLDS ALL PRODUCT RIGHTS FOR PCSK9 AND ANGPTL3 PROGRAMS OUTSIDE UNITED STATES
* VERVE THERAPEUTICS INC: VERVE RETAINS CONTROL OF DEVELOPMENT AND COMMERCIALIZATION OF ALL COLLABORATION PRODUCTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments